Global Pharmacogenomics Market Share Grows at a Staggering CAGR of 6.6%

Pharmacogenomics is a wide field comprising the study of genome reaction to drugs, combining the field of pharmacology and genomics. It helps to understand how individual genetic differences influence drug efficacy and the adverse events. The major factor propelling the growth of the market is growing focus on precision medicine and personalized therapeutics, increasing incidences of adverse drug reaction, and growing direct-to-consumer genetic testing. Further, the development of multi-gene pharmacogenomics panels and increasing integration in oncology for targeted therapies present significant opportunities in the market.

Market Dynamics

Clinical pharmacogenomic guidelines expansion drives the demand for pharmacogenomics

The expansion of clinical pharmacogenomic guidelines is a major driver of the pharmacogenomics market, enabling standardized, evidence-based integration of genetic data into clinical practice. Organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have been pivotal in publishing actionable, peer-reviewed guidelines that link genetic variants to drug responses.

• As of 2024, CPIC has released over 40 gene–drug guidelines, covering critical areas such as antidepressants, cardiovascular drugs, and oncology therapies.
• A study published in The Lancet Digital Health in 2023 found that 71% of U.S. healthcare systems implementing pharmacogenomics rely on CPIC guidelines, highlighting their clinical influence.

Thus, the increasing number of such guidelines encourages more hospitals and healthcare providers to adopt pharmacogenomic testing, thereby accelerating market growth and supporting the clinical utility of pharmacogenomics worldwide.

Partnerships between hospitals and genomics labs: Key market opportunity

Strategic partnerships between hospitals and genomics laboratories present a significant opportunity in the pharmacogenomics market by facilitating faster adoption of personalized medicine. These collaborations help integrate pharmacogenomic testing directly into clinical workflows, improving turnaround times and enhancing clinical decision-making. Hospitals benefit from the technological expertise and infrastructure of genomics labs, while labs gain access to real-world patient data and sample volumes.

• For example, in January 2023, Mayo Clinic partnered with Helix, a genomics company, to expand population-scale pharmacogenomic screening within its healthcare system.
• Additionally, according to the National Academy of Medicine, such collaborations have led to a significant increase in pharmacogenomic test adoption in partner hospitals across the U.S.

Such partnerships accelerate the creation of localized gene-drug databases, making therapies safer and more effective. As the demand for tailored treatment grows, hospital-lab alliances are expected to play a vital role in expanding access to actionable genomic insights.

Regional Insights

North America accounted for the major share of 37.6% in pharmacogenomics, owing to strong healthcare infrastructure, well-established reimbursement schemes, and increasing incidences of adverse reaction. The region benefits from a high concentration of key market players, extensive research funding, and integration of pharmacogenomic data into electronic health records (EHRs). Additionally, initiatives such as the U.S. FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling and the NIH’s All of Us Research Program have accelerated clinical adoption. Favorable reimbursement policies and the presence of leading diagnostic labs further contribute to North America's dominant position in the global market.

The Asia Pacific region is anticipated to grow at the fastest CAGR during the forecast period. This growth is driven by increasing investments in genomic research, expanding healthcare infrastructure, and a rising focus on precision medicine across emerging economies. Countries such as China, Japan, South Korea, and India have launched national genome initiatives to map genetic diversity and enhance personalized treatment, encouraging the adoption of pharmacogenomics across the region.

Key Highlights

• The global pharmacogenomics market size was valued at USD 6.13 billion in 2024. It is projected to reach USD 11.17 billion by 2033, growing at a CAGR of 6.6% during the forecast period (2025–2033).
• Based on type, the market is segmented into products, services and software. The product segment accounted for major pharmacogenomics market share, owing to its broad adoption in clinical workflows for genotype-based drug response testing.
• Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, mass spectrometry, microarray and others.The polymerase chain reaction segment dominated the pharmacogenomics sector in 2024. This growth is driven by its cost-effectiveness, rapid results, and widespread use in gene variant detection.
• Based on application, the market is segmented into cardiovascular disease, infectious diseases, oncology, neurological diseases, pain management and trauma and others.The oncology segment dominated the pharmacogenomics sector with the market share of 37.9%. This growth is driven owing to its increasing cancer incidence and demand for precision therapies like targeted and immunotherapies.
• Based on end user, the market is segmented into hospitals, clinical laboratories, pharmaceutical companies, academic research institutions and others. The clinical laboratories segment is expected to grow at the fastest CAGR, due to expansion of decentralized and rapid genetic testing services.

Market Segments

1. By Type
   1. Products
      1. Genotyping Kits
      2. Sequencing Instruments
      3. PCR Reagents and Consumables
      4. Sample Preparation Kits
      5. Others
   2. Services
      1. Genetic Testing Services
      2. Pharmacogenomic Consulting
      3. Others
   3. Software
      1. Bioinformatics Software
      2. Clinical Decision Support System
      3. Laboratory Information Management System
      4. EHR Integration Software
      5. Others
2. By Technology
   1. Next-Generation Sequencing
   2. Polymerase Chain Reaction
   3. Mass Spectrometry
   4. Microarray
   5. Others
3. By Application
   1. Cardiovascular disease
   2. Infectious diseases
   3. Oncology
   4. Neurological diseases
   5. Pain Management and Trauma
   6. Others
4. By End-User
   1. Hospitals
   2. Clinical Laboratories
   3. Pharmaceutical Companies
   4. Academic Research Institutions
   5. Others